Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 233Head and Neck Neoplasms 150Squamous Cell Carcinoma of Head and Neck 136Stomach Neoplasms 117Lung Neoplasms 109Esophageal Neoplasms 90Uterine Cervical Neoplasms 72Neoplasms 67Urinary Bladder Neoplasms 56Breast Neoplasms 48Ovarian Neoplasms 46Esophageal Squamous Cell Carcinoma 45Pancreatic Neoplasms 44Small Cell Lung Carcinoma 42Neoplasm Metastasis 40Adenocarcinoma Of Esophagus 38Carcinoma, Squamous Cell 33Carcinoma, Ovarian Epithelial 32Mesothelioma, Malignant 30Parkinson Disease 4, Autosomal Dominant Lewy Body 28Lymphoma 28Adenocarcinoma of Lung 25Sarcoma 24Cholangiocarcinoma 24Nasopharyngeal Carcinoma 22Carcinoma 22Unspecified Adult Solid Tumor, Protocol Specific 21Neuroblastoma 21Gallbladder Neoplasms 21Central Nervous System Neoplasms 21

Interventions

Trastuzumab 1Paclitaxel 1MM-111 1Lapatinib 1Docetaxel 1Cisplatin 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × HER-2 Gene Amplification × Cisplatin × Clear all
NCT01304784 2015-12-16

A Study of MM-111 in Combination With Multiple Treatments in Patients With HER2 Positive Cancer

Merrimack Pharmaceuticals

Phase 1 Completed
100 enrolled

HER-2 Gene Amplification

Data powered by HemOnc (CC BY 4.0) Colophon âš¡